At 12:01 a.m. Monday the transition heading that has held most branded drug importers at zero since July expires, and the Section 232 pharmaceutical regime reaches everyone outside seventeen named companies. There is no in-transit grace.
WASHINGTON, Sept. 27, 2026 – The second and larger phase of the United States Section 232 pharmaceutical tariff takes effect at 12:01 a.m. Eastern on Monday, Sept. 29, when Harmonized Tariff Schedule heading 9903.04.61 expires and the companies that have been reporting under it start paying.
The regime itself is not new. Proclamation 11020, signed April 2, 2026 and published April 9 at 91 FR 18183, established a 100 percent ad valorem duty on patented pharmaceuticals and their associated ingredients, with a tiered structure of reductions and exemptions. What changed on July 31 was that the duty became payable for the seventeen companies listed in Annex III to the proclamation. What changes Monday is that it becomes payable for everyone else.
This distinction has been widely garbled in trade coverage, and it matters. Annex III is not an exemption list. It is the early effective date list. Most of the companies on it pay nothing, because they hold separate agreements. The companies that have been paying nothing because of a transitional reporting heading are the ones whose bills arrive Monday.
A further point for anyone with freight in the air or on the water: there is no in-transit exception. What governs is the date the goods clear, not the date they shipped.
How the structure actually works
Customs and Border Protection implemented the proclamation through CSMS message 69395344, issued July 30, 2026, which established a table of Chapter 99 headings. The headings are mutually exclusive, and where more than one could apply, clause 8 of the proclamation directs that the lowest applicable rate governs.
Heading 9903.04.60 is the residual: patented pharmaceutical articles at 100 percent.
Heading 9903.04.61 is the transition. It covered patented articles of companies not listed in Annex III, for entries made before Sept. 29, 2026, at a 0 percent additional duty. It was report-only. That heading dies Monday.
Heading 9903.04.62 covers products of Japan, the European Union, the Republic of Korea, and Switzerland and Liechtenstein jointly, at 15 percent.
Heading 9903.04.63 covers products of the United Kingdom. It was set at 10 percent and reduced to zero effective July 31, 2026 by a Federal Register notice published Aug. 4, 2026, on the basis that the requirements of the pharmaceutical pricing arrangement announced in April were being met. The United Kingdom is currently the only jurisdiction at zero on this basis.
Heading 9903.04.64 covers articles of companies with a Commerce-approved onshoring plan, at 20 percent. That rate rises to 100 percent on April 2, 2030.
Heading 9903.04.65 covers companies that hold both an approved onshoring plan and a most favored nation pricing agreement with the Secretary of Health and Human Services, at zero. That treatment expires Jan. 20, 2029.
Heading 9903.04.66 covers drugs for specified uses at zero. Heading 9903.04.67 covers generics at zero. Heading 9903.04.68 covers United States origin active ingredients returned in dosage form at zero. Heading 9903.04.69 covers non-pharmaceutical Chapter 29 and 30 articles and articles that are neither patented nor generic, at zero.
Heading 9903.04.70 is new as of Monday. It covers articles solely for clinical trials, research and development, or non-commercial applications, at zero.
One compliance obligation applies regardless of rate. Since July 31, every importer of goods classified in Chapters 29 and 30 must report an applicable Chapter 99 provision on entry, whether or not additional duty is owed.
Who is inside the wall and who is outside
Annex II to the proclamation lists thirteen companies that had reached pricing and onshoring agreements before the proclamation issued: AbbVie, Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, EMD Serono, Genentech, Gilead Sciences, Merck Sharp & Dohme, Novartis Pharmaceuticals Corporation, Novo Nordisk and Sanofi.
Annex III adds four to that list for purposes of the accelerated effective date: GlaxoSmithKline and ViiV Healthcare, Johnson & Johnson, Pfizer and Regeneron.
Everyone else is outside. That includes Takeda, Bayer, Teva, Sandoz, Astellas, Daiichi Sankyo, Otsuka, UCB, Ipsen, Servier and the entire mid-cap and biotech importing community. For those firms, Monday brings either the 15 percent country rate if the goods originate in the European Union, Japan, Korea or Switzerland, or the 100 percent default if they do not.
The gap between those two outcomes is the whole story for a large number of importers, and it turns on country of origin rather than on where the pill was pressed.
The origin trap
This is the most consequential and least discussed compliance point in the entire regime.
Customs and Border Protection’s settled position is that converting bulk active pharmaceutical ingredient into finished dosage form, by tabletizing, encapsulating or packaging, is not a substantial transformation. Origin generally follows the active ingredient. Ruling HQ H267177, involving acyclovir tablets, is the canonical citation, and the same reasoning has been applied to naproxen, ibuprofen and valsartan.
The practical consequence is stark. Finishing a drug from Chinese or Indian active ingredient in the United Kingdom or the European Union will not, without more, confer United Kingdom or European Union origin. Alvarez & Marsal made this point directly in an August 2026 analysis, warning that tariff engineering around the country tiers is constrained by exactly this doctrine.
With rates running from zero for the United Kingdom, to 15 percent for the European Union, Japan, Korea and Switzerland, to 100 percent for everything else, origin determinations now drive the entire duty exposure. An importer that has been filing origin on the basis of final manufacturing site and has never tested that position against CBP’s substantial transformation rulings is carrying a very large unquantified liability as of Monday morning.
What the government changed this week
Two instruments landed in the last seven days.
On Sept. 21, the Bureau of Industry and Security released guidance identifying the specialty pharmaceutical categories eligible for zero treatment. On Sept. 23, the Federal Register published the implementing notice at 91 FR 60360, document 2026-19498, effective Sept. 29.
That notice does four things. It confirms nine specialty categories at zero: drugs whose approved indications are all orphan designations, nuclear medicines, plasma derived therapies, fertility drugs, cell therapy, gene therapy, antibody drug conjugates, chemical, biological, radiological and nuclear medical countermeasures, and animal health products.
It lists the nineteen jurisdictions whose products can qualify for that treatment: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. India’s inclusion is worth noting given its weight in American drug supply.
It makes five technical corrections to Annex I. The generic definition is amended to include unpatented animal health products. Heading 9903.04.70 is created. The term pharmaceutical articles is clarified to cover finished products, active ingredients and key starting materials alike. Heading 9903.04.69 is clarified. Tariff schedule updates from July 1, 2026 are incorporated.
It also removes five overlapping codes from Annex IV, the exclusion list: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00 and 3004.49.00.
Finally, it opens a rolling submission process for urgent health need determinations. Companies may write to pharma232 at bis.doc.gov with organizational details, full product identification including tariff classification and investigational new drug number, and a rationale addressing the disease, available alternatives, patient population and international availability. Commerce decides in consultation with USTR and the Department of Health and Human Services, issues determinations in writing on a company-specific basis, and transmits them to CBP.
No last-minute delay or general exemption was announced. The Monday date stands.
What “patented” means for classification
Under United States Note 40, an article is patented for these purposes if it is both subject to a valid, unexpired United States patent and listed in the Food and Drug Administration’s Orange Book for drugs or Purple Book for biologics.
That definition does real work. It means classification requires a patent and listing check for every product line, not merely a judgment about whether a drug is branded. It also means the scope reaches upstream: the same rate applies to the finished product, its active ingredients and its key starting materials.
For importers, that is a two-part exercise. Every stock keeping unit needs a determination of whether it falls in Annex I or Annex IV, a patent and listing status check, a country of origin determination that survives the substantial transformation analysis, and then the correct Chapter 99 heading. Only after all four is a landed cost model reliable.
The generics paradox
Clause 5 of the proclamation states that “generic pharmaceuticals and their associated ingredients shall not be subject to tariffs pursuant to section 232 at this time,” and directs Commerce to advise the President within one year, which is to say by April 2, 2027, on whether to extend the tariffs to generics.
That sounds like a clean exemption. It is not.
The Section 301 forced labor tariffs that took effect July 24, 2026 across 60 economies carry a pharmaceutical carve-out, but the carve-out is lopsided. According to Alvarez & Marsal’s August analysis, the Section 301 pharmaceutical exclusion list contains roughly 577 Chapter 29 provisions, covering bulk chemicals and active ingredients, but only a single Chapter 30 provision. Chapter 30 is where finished dosage forms sit.
The result is that generic finished dosage forms are exposed to the full forced labor tariff of 10 to 12.5 percent depending on origin, even though they are at zero under Section 232. Generics escaped the pharmaceutical tariff and were caught by the forced labor one.
For an industry with the economics the generic sector has, that is not a small matter. Generic medicines account for roughly 90 percent of American prescriptions but only about 13 percent of drug spending, according to the Association for Accessible Medicines. John Murphy III, the association’s president and chief executive, has described the margin position bluntly, saying in February 2025 that “generic manufacturers simply can’t absorb new costs. Our manufacturers sell at an extremely low price, sometimes at a loss, and are increasingly forced to exit markets where they are underwater.”
Richard Saynor, chief executive of Sandoz, put the pass-through question more directly in September 2026 remarks reported by CNBC Africa: “Patients pay the tariff.” He added that “any business is not going to systematically continue to supply a product at a material loss. So you either then have a choice of putting the price up or not supplying the product.”
There is a further cloud over generics. In late July 2026 the President announced a phased generic tariff, at zero until August 2028, then 100 percent, rising to 200 percent in 2029. No implementing proclamation or Federal Register instrument for that announcement has been located. It should be treated as announced, not enacted. The clause 5 review due in April 2027 is the earlier and more concrete decision point.
The legal ground: Section 232 is now load-bearing
Context that importers should keep in view: on Feb. 20, 2026 the Supreme Court decided Learning Resources, Inc. v. Trump, holding that the International Emergency Economic Powers Act does not authorize the President to impose tariffs. The IEEPA tariffs terminated Feb. 24, 2026 by executive order.
That removed the reciprocal tariff architecture entirely. Any analysis describing pharmaceutical duties stacking with IEEPA reciprocal tariffs is stale. The Section 122 surcharge that bridged the gap expired July 24, 2026 at the end of its 150-day statutory life, and it had excluded pharmaceuticals twice over in any event.
What remains is Section 232, Section 301, and the antidumping and countervailing duty system. Section 232 has survived judicial challenge historically, in cases including Transpacific Steel and American Institute for International Steel, and no court challenge to Proclamation 11020 has been identified.
That last fact is itself notable. The pharmaceutical industry negotiated rather than sued. Thirteen companies signed most favored nation pricing agreements with Health and Human Services, and those agreements are precisely what buys zero-rate treatment under heading 9903.04.65 through Jan. 20, 2029.
The aggregate onshoring commitments are large. Reporting compiled by Think Global Health in late 2025 put the total at roughly $480 billion to $500 billion across fourteen companies, spanning 22 new manufacturing sites and approximately 44,000 jobs. Commerce Secretary Howard Lutnick has used a $400 billion figure, telling Breitbart in February 2026 that “these are just huge numbers, 1.2 trillion for semiconductors, 400 billion for pharmaceuticals,” and that “we probably save 100 billion dollars a year for the American Medicaid Medicare system.”
Individual pledges include AbbVie at $100 billion in research and development over a decade, Pfizer and Merck at roughly $70 billion each, Johnson & Johnson at $55 billion, Roche and AstraZeneca at $50 billion each, Gilead at $32 billion, GSK at $30 billion, Eli Lilly at $27 billion, Novartis at $23 billion and Sanofi at $20 billion.
The cliffs nobody is pricing
The exemptions sunset. The zero rate under heading 9903.04.65 expires Jan. 20, 2029. The 20 percent onshoring rate under 9903.04.64 becomes 100 percent on April 2, 2030.
Companies are making twenty-year capital commitments against tariff relief that runs out in three and four years respectively. The onshoring rules also contain anti-gaming provisions that cut against acquisition strategies: the reduced rate does not apply to products acquired after April 2, 2026, nor to products the manufacturer did not develop as a majority participant. Commerce requires audited reports at least semiannually and may reimpose tariffs prospectively and retroactively for fraud or deliberate misrepresentation.
What the numbers say about exposure
Estimates of total American pharmaceutical imports vary by product basket. The Tax Foundation, using 2024 data, put the figure at $225.1 billion, split between $213.8 billion in drugs and medicaments and $11.3 billion in active ingredients, with the European Union supplying $135.6 billion, India $13.0 billion, China $8.7 billion, Japan $7.8 billion and the United Kingdom $7.2 billion. An EY analysis for PhRMA using 2023 data put total imports at $203 billion with 73 percent from Europe.
The Tax Foundation estimated direct tariff payments under the regime at $19.7 billion to $23 billion depending on scenario, with net federal revenue of $15.1 billion to $17.7 billion after income and payroll offsets.
Dependence on imports for generics is higher than the dollar figures suggest. Roughly 90 percent of American generic prescriptions are import dependent, India supplies about half of American generics, and Chinese producers supply a large majority of the active ingredients Indian manufacturers use.
There is also a hangover coming. Atradius reported in January 2026 that global pharmaceutical production rose 9.1 percent in 2025 on tariff anticipation, with Irish output up 41.3 percent and forecast to fall 6.4 percent in 2026, and combined United Kingdom and European Union output up 21.6 percent and forecast to fall 3.7 percent. Inventory built ahead of the tariff will be worked down, and the goods that replace it will carry duty.
The importer playbook
Four moves are available.
Classification comes first. Every line needs its Chapter 99 heading determined before Monday, and origin needs to be defensible under substantial transformation analysis rather than assumed from final manufacturing location.
Foreign trade zones and bonded warehouses run in opposite directions here, which is the practical arbitrage of the week. Covered non-domestic goods admitted to a foreign trade zone on or after the effective date must be admitted in privileged foreign status, which fixes classification and rate at admission and makes the zone a rate lock rather than an avoidance mechanism. A bonded warehouse is the mirror image: duty is assessed at withdrawal for consumption at the rate then in effect, so it defers but does not fix.
Drawback is unusually generous under this proclamation. Clause 10 states plainly that “drawback shall be available with respect to the duties imposed pursuant to this proclamation,” a departure from prior Section 232 actions that excluded it. Three routes are available under 19 U.S.C. 1313: unused merchandise drawback, manufacturing drawback, which is particularly useful where imported active ingredients are formulated and exported, and rejected merchandise drawback. Program approval typically runs four to six months, and a manufacturing ruling from headquarters can take up to a year, so importers who will need drawback should start now rather than after the duties accrue.
Urgent health need petitions to BIS are open on a rolling basis from Sept. 23 for products where supply disruption would harm patients.
One planning lever should be treated with caution. First sale valuation is legally available in principle and is an obvious tool at a 100 percent rate, but no published guidance addresses it under this proclamation specifically. Importers considering it should get advice rather than assume.
The argument nobody has made in court
Two lines of criticism are worth recording, because they frame what happens if the political weather changes.
Stephen Ubl, president and chief executive of PhRMA, said at the time of the proclamation that “tariffs on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments announced in the last year,” noting that two-thirds of medicines consumed in America are already domestically manufactured.
Stephen Ezell of the Information Technology and Innovation Foundation went further in an April 2026 analysis, writing that “these tariffs will hit American patients, especially those who depend on innovative medicines from foreign drugmakers, extremely and unnecessarily hard,” and arguing that entrenching the most favored nation pricing regime through tariff leverage “will inflict serious long-term damage.”
Erica York and Alex Durante of the Tax Foundation framed the incidence question differently, noting in March 2026 that where pricing regulation prevents cost pass-through, pharmaceutical tariffs “will act as a hidden cost on Americans: they would shrink incomes, reduce investment, and lead to less innovation.”
Against that, RBC Capital Markets analyst Trung Huynh called the 15 percent country tier “manageable” and said the overall threat to the sector should be low, a reading that has held for the firms inside the annexes and not for the firms outside them.
What to watch
The Commerce recommendation on extending tariffs to generics is due by April 2, 2027 under clause 5. The most favored nation pricing zero rate expires Jan. 20, 2029. The onshoring rate steps to 100 percent on April 2, 2030. The Section 232 investigation covering personal protective equipment, medical consumables and medical devices, initiated in September 2025, remains open with no action taken.
For Monday itself, the operative advice is narrower. Check CBP’s CSMS feed before filing. CSMS 69395344 appears to remain the governing guidance, but a phase-two message would not be unusual, and an importer that files under an expired heading will be correcting entries rather than paying duty.